I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer (CLERAD-PROBE)

Clinical Trial ID NCT01704586

Rank	Title	Journal	Year	PubWeight™‹?›
1	Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.	Thyroid	2009	35.34
2	Guidelines for radioiodine therapy of differentiated thyroid cancer.	Eur J Nucl Med Mol Imaging	2008	2.67
3	Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.	J Nucl Med	2006	1.86
4	Health-related Quality of Life, depression and anxiety in thyroid cancer patients.	Qual Life Res	2006	1.14
5	Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution.	Ann Surg	2003	1.09
6	Dosimetry and thyroid cancer: the individual dosage of radioiodine.	Endocr Relat Cancer	2010	1.03
7	Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma.	J Surg Oncol	2006	0.99
8	The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.	Eur J Nucl Med Mol Imaging	2011	0.89